Approved Risk Evaluation and Mitigation Strategies (REMS)

REMS@FDA

Contact Us | REMS Resources | Gov Delivery Get REMS Email Alerts | Reports & Data Files

Palynziq (pegvaliase-pqpz)
BLA #761079
REMS last update: 05/24/2018



What is the purpose of the REMS?

The goal of the PALYNZIQ (pegvaliase-pqpz) REMS is to mitigate the risk of anaphylaxis associated with PALYNZIQ by:

  1. Ensuring that prescribers are educated on the risk of anaphylaxis associated with the use of PALYNZIQ
  2. Ensuring that prescribers are educated and adhere to the following:
    • Counsel patients on how to recognize and respond to signs and symptoms of anaphylaxis
    • Enroll patients in the PALYNZIQ REMS
    • Prescribe auto-injectable epinephrine with PALYNZIQ
  3. Ensuring that PALYNZIQ is only dispensed to patients with documentation of safe use conditions
    • Patient education and enrollment in the PALYNZIQ REMS
    • Having auto-injectable epinephrine available at all times
  4. Ensuring that patients are educated on the following:
    • How to recognize and respond to signs and symptoms of anaphylaxis
    • The need to carry auto-injectable epinephrine with them at all times

What do participants need to know?

Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the application holder(s) REMS Website or the approved REMS materials for more information.

View application holder(s) REMS Website See Disclaimer page regarding links to external sites

Healthcare Providers who prescribe Palynziq must:

To become certified to prescribe
  • Review the drug's Prescribing Information.
  • Review the following: Prescriber Guide and REMS Program Overview.
  • Successfully complete the Prescriber Knowledge Assessment and submit it to the REMS Program.
  • Enroll in the REMS by completing the Prescriber Enrollment Form and submitting it to the REMS Program.
Before treatment initiation (first dose)
  • Assess the patient's need for an adult observer and for premedication as described in the Prescriber Guide.
  • Counsel the patient on the risk for anaphylaxis, including how to recognize and respond to signs and symptoms of anaphylaxis and having auto-injectable epinephrine available at all times using the Patient Guide, Safety Video, and Wallet Card.
  • Provide the patient with the Patient Guide and Wallet Card, and direct the patient to PALYNZIQREMS.com to view the Safety Video.
  • Enroll the patient in the REMS Program by completing and submitting the Patient Enrollment Form. Provide a completed copy of the form to the patient and retain a completed copy in the patient's record.
  • Provide the patient with a prescription for auto-injectable epinephrine to accompany the prescription for Palynziq.
During treatment; before each prescription
  • Assess the patient for anaphylaxis episodes.
  • Assess the patient's supply of auto-injectable epinephrine.
  • Provide a prescription for auto-injectable epinephrine, if the patient's supply is inadequate.
At all times
  • Report anaphylaxis episodes to the REMS Program.
  • Report treatment discontinuation or transfer of care to the REMS Program.

Patients who are prescribed Palynziq must:

Before treatment initiation
  • Review the Patient Guide, Safety Video, and Wallet Card.
    | Safety Video |
  • Enroll in the REMS Program by completing the Patient Enrollment Form with the prescriber. Enrollment information will be provided to the REMS Program.
  • Receive counseling from the prescriber on how to recognize and respond to signs and symptoms of anaphylaxis, and having auto-injectable epinephrine with you at all times using the Patient Guide, Safety Video, and Wallet Card.
  • Adhere to the safe use conditions including obtaining auto-injectable epinephrine.
At all times
  • Inform the prescriber if you have a severe allergic reaction (anaphylaxis).
  • Inform the prescriber if you need more auto-injectable epinephrine.
  • Have auto-injectable epinephrine and the Wallet Card with you.
  • Inform all doctors about this treatment.
  • Report a change in prescriber or contact information to the REMS Program.
  • Report treatment discontinuation to the REMS Program.

Pharmacies that dispense Palynziq must:

To become certified to dispense
  • Designate an authorized representative to carry out the certification process and oversee implementation and compliance with the REMS Program on behalf of the pharmacy.
  • Have the authorized representative review the REMS Program Overview.
  • Have the authorized representative enroll in the REMS Program by completing and submitting the Pharmacy Enrollment Form.
  • Establish processes and procedures to verify and document the patient has auto-injectable epinephrine and report anaphylaxis episodes to the REMS Program/manufacturer/prescriber.
  • Train all relevant staff involved in the dispensing of Palynziq on the program requirements using the REMS Program Overview.
Before Dispensing
  • Verify and document that the patient has auto-injectable epinephrine through the processes and procedures established as a requirement of the REMS Program.
  • Obtain authorization to dispense each prescription by contacting the REMS Program to verify prescriber certification and patient enrollment.
To maintain certification to dispense
  • Have the new authorized representative enroll in the REMS Program by completing the Pharmacy Enrollment Form if the authorized representative changes.
At all times
  • Report anaphylaxis episodes to the REMS Program.
  • Not distribute, transfer, loan, or sell Palynziq, except to certified dispensers.
  • Maintain records documenting staff's completion of REMS training.
  • Maintain records that all processes and procedures are in place and are being followed.
  • Comply with audits carried out by BioMarin or a third party acting on behalf of BioMarin to ensure that all processes and procedures are in place and are being followed.

Wholesalers that distribute Palynziq must:

To be able to distribute
  • Establish processes and procedures to ensure that the drug is distributed only to certified pharmacies.
  • Train all relevant staff involved in distributing on the REMS Program requirements.
At all times
  • Distribute only to certified pharmacies and maintain records of all distributions.
  • Comply with audits carried out by BioMarin or a third party acting on behalf of BioMarin to ensure that all processes and procedures are in place and are being followed.

What materials are included in the REMS?

The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers. For a specific Medication Guide of a product in the Palynziq REMS, see the DailyMed link(s).
Material Name Material Name Link
Patient Enrollment Form (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Palynziq_2018_05_24_Patient_Enrollment_Form.pdf
Patient Guide (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Palynziq_2018_05_24_Patient_Guide.pdf
Pharmacy Enrollment Form (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Palynziq_2018_05_24_Pharmacy_Enrollment_Form.pdf
Prescriber Enrollment Form (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Palynziq_2018_05_24_Prescriber_Enrollment_Form.pdf
Prescriber Guide (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Palynziq_2018_05_24_Prescriber_Guide.pdf
Prescriber Knowledge Assessment (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Palynziq_2018_05_24_Prescriber_Knowledge_Assessment.pdf
REMS Document (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Palynziq_2018_05_24_REMS_Document.pdf
REMS Full (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Palynziq_2018_05_24_REMS_Full.pdf
REMS Program Overview (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Palynziq_2018_05_24_REMS_Program_Overview.pdf
REMS Program Website Screenshots (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Palynziq_2018_05_24_REMS_Program_Website_Screenshots.pdf
Safety Video (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Palynziq_2018_05_24_Safety_Video.pdf
Wallet Card (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Palynziq_2018_05_24_Wallet_Card.pdf

What updates have been made to the REMS?

Date Summary of change
05/24/2018 Approval of the REMS.

Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English